Abstract: Rocket Pharma announced that its in vivo gene therapy Kresladi (libmeldagene autotelcel) has recently received FDA approval for the treatment of infantile Pompe disease (IOPD) . This is the world's first one-time gene therapy for this disease, delivering a functional GAA gene to repair the defect at its source, overcoming the limitation of traditional enzyme replacement therapy requiring lifelong treatment, and bringing new hope for survival to severely affected children.

I. FDA Approval Finally Granted! Kresladi Opens a New Chapter in Pompe Disease Treatment

Let's look at the key news first: Rocket Pharma's Kresladi has received FDA approval, becoming the first approved one-time gene therapy for infantile Pompe disease . This drug uses an adeno-associated virus (AAV) vector to target and deliver the drug to the patient's liver, where it continuously expresses the functional GAA enzyme. I've been following the clinical progress of this drug for over two years, from early clinical trials to final approval; every step has been a source of great anxiety for families with rare diseases. Its launch directly fills the gap in curative treatment in this field.
II. Correcting the problem at its root: One-time administration, bidding farewell to the lifelong treatment model

Infantile Pompe disease stems from a defect in the GAA gene , causing a deficiency of a key enzyme that leads to glycogen buildup and damage to the heart and skeletal muscles. The traditional standard treatment is enzyme replacement therapy (ERT) , which requires regular intravenous infusions and cannot completely cure the condition. Kresladi's core advantage is a single intravenous administration that repairs the defect at the genetic level, allowing the body to produce the enzyme itself. Many families with affected children suffer from the burden of long-term intravenous infusions; this drug truly offers a one-time treatment with long-term benefits.
III. Impressive Clinical Data: Comprehensive Improvement in Exercise, Respiration, and Cardiac Function

Kresladi's approval was based on pivotal clinical trial data, showing significant improvements in motor development, respiratory function, and cardiac parameters in infants with IOPD treated with it . Compared to traditional therapies, children no longer need frequent hospital visits for medication infusions, resulting in a substantial improvement in their quality of life. I've seen follow-up videos of children after treatment; previously weak babies can now roll over and move around normally. Such changes are far more meaningful to families with children suffering from rare diseases than the medication itself.
IV. Behind the Exorbitant Prices of Therapies: The Realities and Challenges of Gene Therapies for Rare Diseases

Gene therapy research and development costs are extremely high, and Kresladi, as a one-time cure, will inevitably be priced high. Rocket has not yet announced a specific price, but based on similar rare disease gene therapy drugs, the cost will likely exceed one million dollars. How to streamline payment processes and ensure that the drug truly reaches affected children is a challenge that pharmaceutical companies, medical insurance, and all sectors of society must face together.
V. Accelerated in vivo gene therapy ushers in a golden age for the treatment of rare diseases.

The approval of Kresladi further validates the maturity of AAV in vivo gene therapy in the field of rare diseases. Rocket will also build a commercialization team around this drug to advance patient accessibility. We suggest you continue to pay attention, as the technology matures and the payment system improves, more and more rare diseases will move from "untreatable" to "cured with a single injection".
Reference source: https://www.fiercepharma.com/pharma/rocket-charts-measured-trajectory-new-gene-therapy-kresladi-after-clearance-launch-fda

https://mp.weixin.qq.com/s/AmxIqrolHjasao4yyf5dlA